Just been looking at Novo Nordisk and honestly, this might be one of the best undervalued stocks nobody's talking about right now. The stock got absolutely hammered down 66% from last year's highs, especially after that weak 2026 guidance. But here's the thing—if you're looking for value plays with actual catalysts, this deserves a second look.

So what went wrong? Novo Nordisk was actually first to the GLP-1 party with Wegovy, but they couldn't scale fast enough. Eli Lilly swooped in with Mounjaro and Zepbound, which hit harder and faster. Now Eli Lilly's basically dominating the space. Add to that the company's disappointing 2026 outlook—they're expecting revenue and earnings to drop, partly due to U.S. drug pricing negotiations. Yeah, it's easy to see why everyone's written them off.

But wait. Here's what I think people are missing. Novo Nordisk just launched the pill version of their GLP-1 drug before Eli Lilly even got theirs out. That matters because most people would obviously prefer taking a pill over getting shots. The uptake on their pill has been surprisingly strong, which suggests there's real demand waiting to be captured. They're also working on a better formulation to compete more directly with Eli Lilly's offering.

Now let's talk valuation because this is where it gets interesting. Novo Nordisk trades at a 13.5 P/E ratio compared to Eli Lilly's 45. That's a massive gap. And the dividend yield is 3.7% versus Eli Lilly's 0.6%—with a solid 40% payout ratio so it's actually sustainable. When you're looking at best undervalued stocks in the pharma space, these numbers jump out.

The real play here is that 2026 might actually be a turnaround year. If the pill gains traction and they execute on their competitive improvements, they could recapture meaningful market share. For dividend investors or anyone with a value bent, Novo Nordisk looks like one of the best undervalued stocks right now in this sector. Not saying it's a slam dunk, but the risk-reward is definitely tilted in your favor at these prices.